

**UK MYELOMA FORUM**  
**ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 MARCH 2021**

# UK MYELOMA FORUM

## LEGAL AND ADMINISTRATIVE INFORMATION

---

### Trustees

Prof G Cook  
Dr J Ashcroft  
Dr N Rabin  
Dr G Pratt  
Dr M Kaiser  
Dr K Ramasamy  
Dr S Stern  
Dr R Popat  
Dr M Jenner  
S Henshaw  
Dr S Lawless  
Dr R Soutar  
Dr R Hall  
Dr J Sive  
Dr S Lawson  
Dr M Streetly  
Dr C Bygrave  
L Kerby

### Charity number

1082702

### Principal address

Royal Bournemouth Hospital  
Castle Lane East  
Bournemouth  
BH7 7DW

### Independent examiner

Joel Courts  
c/o HW Fisher LLP  
Chartered Accountants  
Acre House  
11-15 William Road  
London  
NW1 3ER

### Bankers

Adam & Co  
25 St Andrew Square  
Edinburgh  
EH2 1AF

---

# UK MYELOMA FORUM

## CONTENTS

---

|                                   | Page    |
|-----------------------------------|---------|
| Trustees' report                  | 1 - 7   |
| Independent examiner's report     | 8       |
| Statement of financial activities | 9       |
| Balance sheet                     | 10      |
| Notes to the accounts             | 11 - 17 |

---

| Trustees' Annual Report for the period |  |                   |       |      |                 |       |            |
|--|--|-------------------|-------|------|-----------------|-------|------------|
| From                                   |  | Period start date |       |      | Period end date |       |            |
|  |  | Day               | Month | Year | Day             | Month | Year       |
|  |  | 1                 | April | 2020 | To              | 31    | March 2021 |

## Section A Reference and administration details

|   |                            |         |  |
|---|----------------------------|---------|--|
| <b>Charity name</b>                       | UK Myeloma Forum           |         |  |
| <b>Other names charity is known by</b>    | UKMF                       |         |  |
| <b>Registered charity number (if any)</b> | 1082702                    |         |  |
| <b>Charity's principal address</b>        | Royal Bournemouth Hospital |         |  |
|   | Castle Lane East           |         |  |
|   | Bournemouth                |         |  |
|   | <b>Postcode</b>            | BH7 7DW |  |

### Names of the charity trustees who manage the charity

|     | Trustee name                           | Office (if any)        | Dates acted if not for whole year   | Name of person (or body) entitled to appoint trustee (if any) |
|-----|--|------------------------|-------------------------------------|---|
| 1.  | Dr John Ashcroft<br>(Leeds, Mid Yorks) | Chair / Board member   | Chair November 2015 - November 2021 |   |
| 2.  | Dr Rachel Hall<br>(Bournemouth)        | Board Member/Treasurer | November 2019 -November 2023        |   |
| 3.  | Prof Gordon Cook<br>(Leeds)            | Past Chair/HTA lead    | November 2019- November 2021        |   |
| 4.  | Dr Neil Rabin<br>(London)              | Chair Elect            | January 2013 - November 2021        |   |
| 5.  | Dr Guy Pratt<br>(Birmingham)           | Secretary              | November 2013-November 2023         |   |
| 6.  | Dr Martin Kaiser<br>(London)           | Board member           | January 2018 – January 2022         |   |
| 7.  | Dr Karthik Ramasamy<br>(Oxford)        | Communications Lead    | November 2014 - June 2022           |   |
| 8.  | Dr Simon Stern<br>(Surrey)             | Guidelines Secretary   | June 2017 - June 2023               |   |
| 9.  | Dr Matthew Streetly<br>(London)        | Advocacy lead          | January 2014 - January 2020         |   |
| 10. | Dr Rakesh Popat<br>(London)            | Science Lead           | November 2018 - November 2021       |   |
| 11. | Dr Matthew Jenner<br>(Southampton)     | Board member           | March 2018 - March 2022             |   |

|     |                                   |   |                              |  |
|-----|-----------------------------------|---|------------------------------|--|
| 12. | Dr Jonathan Sive<br>(London)      | Board member  | January 2020 -January 2023   |  |
| 13. | Sarah Henshaw<br>(Nottingham)     | Myeloma Nurse Lead                                    | November 2018 -November 2021 |  |
| 14. | Dr Ceri Bygrave<br>(Cardiff)      | Wales Representative<br>(Invited Board member)        | November 2015 -November 2021 |  |
| 15. | Dr Sarah Lawless<br>(N.Ireland)   | N.Ireland<br>Representative<br>(Invited Board member) | January 2018 -January 2024   |  |
| 16. | Dr Richard Soutar<br>(Glasgow)    | Scotland Representative<br>(Invited Board member)     | December 2017 -January 2024  |  |
| 17. | Dr Michelle Lawson<br>(Sheffield) | Board member  | January 2020 – January 2023  |  |

**Names of the trustees for the charity, if any, (for example, any custodian trustees)**

| Name | Dates acted if not for whole year |
|------|-----------------------------------|
|      |                                   |

**Names and addresses of advisers (Optional information)**

| Type of adviser             | Name                       | Address                                      |
|-----------------------------|----------------------------|--|
| <b>Independent Examiner</b> | Joel Courts, HW Fisher LLP | Acre House 11-15 William Road London NW1 3ER |
| <b>Bankers</b>              | Adam & Co                  | 25 St Andrew Square, Edinburgh, EH2 1AF      |

**Name of chief executive or names of senior staff members (Optional information)**

|  |
|--|
|  |
|--|

## Section B Structure, governance and management

**Description of the charity's trusts**

|   |                         |
|---|-------------------------|
| Type of governing document<br>(eg. trust deed, constitution)        | Constitution            |
| How the charity is constituted<br>(eg. trust, association, company) | Association             |
| Trustee selection methods<br>(eg. appointed by, elected by)         | Elected from membership |

## Additional governance issues (Optional information)

You **may choose** to include additional information, where relevant, about:

- policies and procedures adopted for the induction and training of trustees;
- the charity's organisational structure and any wider network with which the charity works;
- relationship with any related parties;
- trustees' consideration of major risks and the system and procedures to manage them.

## Section C Objectives and activities

### Summary of the objects of the charity set out in its governing document

The Charity's objects ("the objects") are

1. The advancement of education of the general public, in particular in the treatment of those suffering from myeloma and related disorders, through the promotion and conduct of research and the publication and dissemination of all useful results of such research.
2. The relief of persons suffering from myeloma and related disorders, in particular by
  - a) the development and provision of policy guidelines for their treatment
  - b) promoting an understanding of the issues relating to myeloma and related disorders by encouraging communication and the exchange of information between research groups and healthcare professionals.

### Summary of the main activities undertaken for the public benefit in relation to these objects (include within this section the statutory declaration that trustees have had regard to the guidance issued by the Charity Commission on public benefit)

The UKMF had a further active year in pursuit of its' charitable objectives which are, education, research and advocacy.

To that end three Executive Committee meetings were held in 2020-2021; June 2020, November 2020 and March 2021.

In keeping with our objectives we have made significant progress in a number of key areas including educational meetings, guidelines and advocacy. These are summarised in the following pages.

## Additional details of objectives and activities (Optional information)

You **may choose** to include further statements, where relevant, about:

- policy on grantmaking;
- policy programme related investment;
- contribution made by volunteers.

Revenue for corporate sponsorship contributed £133,560 ( April 2020-March 2021). This re-enforces the support by pharma for the work that the UKMF undertakes.

Due to Covid-19, the Autumn Day became an entirely virtual meeting and was held on 11th November 2020. The programme theme was 'Accelerating Research: Better Trial Designs, Better Therapies' and featured Professor Mohamad Mohty from Saint Antoine Research Centre, Paris. Prof. Mohty presented the Michael Morley Lecture on 'A journey from past to future'.

The Spring Day was also a virtual meeting and was held on 17<sup>th</sup> March 2021. The theme for this meeting was the, 'Impact of Covid on Multiple Myeloma Management'. The plenary lecture was given by Dr Maheshi Ramasamy from the University of Oxford. Her talk was entitled, 'The Oxford Astra Zeneca vaccine-developing a global vaccine against COVID-19.

A number of travel grants for scientific conferences were awarded in 2020 to winning abstracts. Three bursaries of £350 covered the registration fee for ASH (American Society of Haematology Annual Meeting). This meeting was virtual due to Covid-19 travel restrictions. The ASH abstracts were presented at the Spring Day in March 2021. A review of ASH was produced in the e-newsletter. Initially, two travel grants of £700 were awarded to attend the EMN meeting (European Myeloma Network) from 16<sup>th</sup> -18<sup>th</sup> April 2020 in Amsterdam. However, this meeting was cancelled and later postponed to March 2021 due to the global pandemic. The bursary funds have been returned to the UKMF.

## Section D

## Achievements and performance

**Summary of the main achievements of the charity during the year**

### **The annual meetings**

Producing two successful and well attended educational meetings on a new virtual platform in November 2020 and March 2021. For details, please refer to the section above and the UKMF website for programme and talks from these meetings.

Please refer to the UKMF website for the programme and talks from the education meeting.

### **Travel grants for scientific meetings**

The UKMF in collaboration with the Michael Morley Fund awarded a number of bursaries in 2020-21 to support the attendance of young investigators and specialist nurses at ASH Virtual (American Society of Haematology Meeting) in December 2020. Recipients of the bursaries presented their data at the UKMF Spring Day in March 2021. This is a regular and successful session. For the ASH bursary winners, recipients prepared a short review for the UKMF website and were credited in the UKMF e-newsletter.

### **Advocacy**

The UKMF members have continued to engage with the NICE technology appraisals both in newly diagnosed and relapsed myeloma. Members of the UKMF also help develop NICE clinical guidelines and more recently input into NHS England Algorithm.

### **The Guidelines group**

The UKMF Guidelines Group remained active despite the difficulties caused by the Covid-19 pandemic, good progress had been made on the development of 2 new separate sets of guidelines on the management of both newly diagnosed and relapsed multiple myeloma.

A full first draft of the newly diagnosed guidelines had been reviewed by the BSH Haemato-oncology Task Force and BSH Guidelines Committee. A first full draft of the relapsed guidelines was near completion.

In addition, writing groups had been set up with a view to producing Good Practice Papers (GPPs) on the diagnosis and management of both MGUS and MGRS.

#### **Myeloma Nurse Group**

Due to COVID, the Nurse group understandably had not been as active in 2020. However, the group planned to pull together details on the impact of COVID to Myeloma Nursing Care in preparation for the Spring Day 2021. The nurse group also planned to do a best practice guide for Peripheral Neuropathy.

#### **College of Myeloma (UK)**

Created in 2019, the College of Myeloma (UK) consists of elected fellows representing those who have contributed significantly to the work of the UKMF and to patients with Myeloma through medical science, education and clinical care.

- Fellows will be nominated and elected to the College.
- Elected fellows will be known as Fellows of the College of Myeloma (UK) and can use the designation of F.C.My.(UK), should they wish.
- The College will be led by a Dean (Professor Gordon Cook), elected from the College fellowship on a 3 yearly basis.
- The aim is to elect one fellow per year.
  - two fellows will be elected each year for the first 5 years
  - then one per year afterwards.
  - Until the College has a core of fellows, the UKMF Executive committee shall vote on the nominees for each year.

The election process will be coordinated by the sitting past-Chair of the UKMF, both in the first five years of establishing the College, and thereafter thus ensuring the continually engagement and involvement by the UKMF in the establishment of the College

The Fellows of the College will provide guidance to the Society in order for the Society to deliver on its organisational strategy. Consequently, Fellows of the College will serve to:

- Individually, provide expert input to the delivery of medical education, either through advice on content or the provision of content in line with the UKMF Education strategy.
- Individually, provide mentorship for developing professionals in the field of plasma cell disorders, to assist in career development.
- Individually, where appropriate, assist in the governance of the clinical research program as directed by the Society's research strategy delivered through the UK Myeloma Research Alliance
- Collectively provide advice and guidance on patient advocacy in accordance with the Society's advocacy strategy.
- Collectively provide support and guidance on matters of public policy, health technology appraisals and national service delivery strategies as affect patients with myeloma.

2019 fellows : Professor Curly Morris  
Professor Kwee Yong

2020 fellows : Professor Keith Stewart  
Professor Steve Schey

2021 fellows: Professor Graham Jackson  
Dr Jenny Bird  
Professor Mark Cook



## Section E Financial review

### Brief statement of the charity's policy on reserves

The UKMF's policy on reserves is to maintain sufficient level of funds to enable operating activities to be supported, taking account of potential risks and contingencies that may arise from time to time. The policy is reviewed annually by the Trustees.

### Details of any funds materially in deficit

Not applicable

### Further financial review details (Optional information)

You **may choose** to include additional information, where relevant about:

- the charity's principal sources of funds (including any fundraising);
- how expenditure has supported the key objectives of the charity;
- investment policy and objectives including any ethical investment policy adopted.

#### Income

Education Grants from Corporate Sponsors contributed £133,560 in the year 2020-2021. £68,261 was received in 2019-2020.

Micheal Morley fund at the end of the 2020-2021 tax year stood at £277,212 compared to £233,148 in the previous year.

Total income from the 2020-2021 year was £137,923 (2020: £73,859).

#### The Michael Morley Fund

This fund is a charitable donation from a patient's estate that is invested on behalf of the UKMF and the interest may be used towards certain projects including supporting two Michael Morley lectures per annum. See section D for further details).

#### Expenditure

Administrative costs (covering Executive meetings and associated expenses and the salary and on-costs of our Administrative Secretary, accountants' fees, employer's liability insurance and teleconferencing) at £34,412 (2020: £34,291).

Spring and Autumn educational meetings in the 20-21 year at £17,217 (2020: £44,730).

Travel bursaries to ASH 2020 amounting to £1,050 (2020: £6,000).

#### Reserves


The UKMF's unrestricted reserves remain sound as of 31st March 2021 and were approximately £137,617 (2020: £57,357).

## Section F Other optional information

## Section G Declaration

The trustees declare that they have approved the trustees' report above.

Signed on behalf of the charity's trustees

|  |   |  |
|--|---|--|
| <b>Signature(s)</b>                        |  |  |
| <b>Full name(s)</b>                        | Dr Rachel Hall  |  |
| <b>Position (eg Secretary, Chair, etc)</b> | Treasurer   |  |
| <b>Date</b>                                | 28 Jan 2022   |  |

# UK MYELOMA FORUM

## INDEPENDENT EXAMINER'S REPORT

### TO THE TRUSTEES OF UK MYELOMA FORUM

---

I report to the trustees on my examination of the financial statements of UK Myeloma Forum (the charity) for the year ended 31 March 2021.

#### **Responsibilities and basis of report**

As the trustees of the charity you are responsible for the preparation of the financial statements in accordance with the requirements of the Charities Act 2011 (the 2011 Act).

I report in respect of my examination of the charity's financial statements carried out under section 145 of the 2011 Act. In carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.

#### **Independent examiner's statement**

Your attention is drawn to the fact that the charity has prepared financial statements in accordance with Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has now been withdrawn.

I understand that this has been done in order for financial statements to provide a true and fair view in accordance with Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2015.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

- 1 accounting records were not kept in respect of the charity as required by section 130 of the 2011 Act; or
- 2 the financial statements do not accord with those records; or
- 3 the financial statements do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

*Joel Courts*

Joel Courts  
c/o HW Fisher LLP  
Chartered Accountants  
Acre House  
11-15 William Road  
London  
NW1 3ER

28 Jan 2022

Dated: .....

# UK MYELOMA FORUM

## STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT

**FOR THE YEAR ENDED 31 MARCH 2021**

|                                       |       | Unrestricted<br>funds<br>general<br>2021<br>£ | Unrestricted<br>funds<br>designated<br>2021<br>£ | Total<br>2021<br>£ | Unrestricted<br>funds<br>general<br>2020<br>£ | Unrestricted<br>funds<br>designated<br>2020<br>£ | Total<br>2020<br>£ |
|---------------------------------------|-------|---|--|--------------------|---|--|--------------------|
|                                       | Notes |   |  |                    |   |  |                    |
| <b>Income from:</b>                   |       |   |  |                    |   |  |                    |
| Donations and legacies                | 3     | 133,560                                       | -  | 133,560            | 68,261  | -  | 68,261             |
| Investments                           | 4     | 29  | 4,334  | 4,363              | 301   | 5,297  | 5,598              |
| <b>Total income</b>                   |       | 133,589                                       | 4,334  | 137,923            | 68,562  | 5,297  | 73,859             |
| <b>Expenditure on:</b>                |       |   |  |                    |   |  |                    |
| Raising funds                         | 5     | -   | 1,436  | 1,436              | -   | 1,542  | 1,542              |
| Charitable activities                 | 6     | 53,329  | -  | 53,329             | 85,896  | -  | 85,896             |
| <b>Total resources expended</b>       |       | 53,329  | 1,436  | 54,765             | 85,896  | 1,542  | 87,438             |
| Net gains/(losses) on investments     | 11    | -   | 41,166   | 41,166             | -   | (27,595)   | (27,595)           |
| <b>Net movement in funds</b>          |       | 80,260  | 44,064   | 124,324            | (17,334)                                      | (23,840)   | (41,174)           |
| Fund balances at 1 April 2020         |       | 57,357  | 233,148  | 290,505            | 74,691  | 256,988  | 331,679            |
| <b>Fund balances at 31 March 2021</b> |       | 137,617                                       | 277,212  | 414,829            | 57,357  | 233,148  | 290,505            |

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

# UK MYELOMA FORUM

## BALANCE SHEET

AS AT 31 MARCH 2021

|   | Notes | 2021<br>£      | £              | 2020<br>£       | £              |
|---|-------|----------------|----------------|-----------------|----------------|
| <b>Fixed assets</b>                                   |       |                |                |                 |                |
| Investments   | 12    |                | 218,212        |                 | 174,148        |
| <b>Current assets</b>                                 |       |                |                |                 |                |
| Debtors   | 13    | 283            |                | 1,430           |                |
| Cash at bank and in hand                              |       | 202,392        |                | 162,266         |                |
|   |       | <u>202,675</u> |                | <u>163,696</u>  |                |
| <b>Creditors: amounts falling due within one year</b> | 14    | <u>(6,058)</u> |                | <u>(47,339)</u> |                |
| Net current assets                                    |       |                | 196,617        |                 | 116,357        |
| <b>Total assets less current liabilities</b>          |       |                | <u>414,829</u> |                 | <u>290,505</u> |
| <b>Income funds</b>                                   |       |                |                |                 |                |
| Unrestricted funds - designated                       | 15    |                | 277,212        |                 | 233,148        |
| Unrestricted funds - general                          |       |                | 137,617        |                 | 57,357         |
|   |       |                | <u>414,829</u> |                 | <u>290,505</u> |

28 Jan 2022

The financial statements were approved by the Trustees on .....



.....

Dr Rachel Hall

Trustee

# UK MYELOMA FORUM

## NOTES TO THE FINANCIAL STATEMENTS

### FOR THE YEAR ENDED 31 MARCH 2021

---

#### 1 Accounting policies

##### Charity information

UK Myeloma Forum is a charity registered in England and Wales and is governed by its constitution. The Charity meets the definition of a public benefit entity under FRS 102. The registered office is Department of Haematology, Royal Bournemouth Hospital, Bournemouth, Dorset, BH14 9QN

##### 1.1 Accounting convention

The accounts have been prepared in accordance with the charity's constitution, the Charities Act 2011 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective from 1 January 2019). The charity is a Public Benefit Entity as defined by FRS 102.

The charity has taken advantage of the provisions in the SORP for charities applying FRS 102 Update Bulletin 1 not to prepare a Statement of Cash Flows.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, modified to include certain financial instruments at fair value. The principal accounting policies adopted are set out below.

##### 1.2 Going concern

The trustees have considered the effect of the prolonged Covid-19 outbreak. The trustees consider that the outbreak is unlikely to cause significant disruption to the charity's activities and are confident that the charity can continue as a going concern for a period of at least 12 months from the date of approval of these financial statements. The trustees have a reasonable expectation that the charity has adequate resources to continue in operation for the foreseeable future.

##### 1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives.

##### 1.4 Incoming resources

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Dividends arising on equity investments are accounted for in the year they are due and receivable.

Interest receivable on fixed interest securities and cash deposits is accrued.

##### 1.5 Resources expended

Liabilities are recognised as expenditure once there is a legal or constructive obligation committing the charity to that expenditure, it is probable that settlement will be required and the amount of the obligation can be measured reliably.

The costs of generating funds consist of investment management fees.

Governance costs comprise all costs involving the public accountability of the charity and its compliance with regulation and good practice.

All expenditure is accounted for on an accruals basis. All expenses, including support costs and governance costs, are allocated to the one charitable activity in the statement of financial activities.

# UK MYELOMA FORUM

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

### FOR THE YEAR ENDED 31 MARCH 2021

#### 1 Accounting policies

(Continued)

Irrecoverable VAT is charged against the expenditure heading for which it was incurred.

##### 1.6 Fixed asset investments

Fixed asset investments are initially measured at transaction price excluding transaction costs, and are subsequently measured at fair value at each reporting date. Changes in fair value are recognised in net income/(expenditure) for the year. Transaction costs are expensed as incurred.

##### 1.7 Financial instruments

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value, with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

##### 1.8 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

##### 1.9 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

#### 2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

The trustees do not consider there to be any critical accounting estimates or judgements applied in the preparation of the financial statements.

#### 3 Donations and legacies

|           | Unrestricted<br>funds<br>general<br>2021<br>£ | Unrestricted<br>funds<br>general<br>2020<br>£ |
|-----------|---|---|
| Donations | 133,560                                       | 68,261  |

# UK MYELOMA FORUM

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2021

### 4 Investments

|                   | Unrestricted<br>funds<br>general<br>2021<br>£ | Unrestricted<br>funds<br>designated<br>2021<br>£ | Total<br>2021<br>£ | Unrestricted<br>funds<br>general<br>2020<br>£ | Unrestricted<br>funds<br>designated<br>2020<br>£ | Total<br>2020<br>£ |
|-------------------|---|--|--------------------|---|--|--------------------|
| Investment income | 29  | 4,334  | 4,363              | 301   | 5,297  | 5,598              |

### 5 Raising funds

|                            | 2021<br>£ | 2020<br>£ |
|----------------------------|-----------|-----------|
| Investment management fees | 1,436     | 1,542     |
|                            | 1,436     | 1,542     |

### 6 Charitable activities

|  | 2021<br>£ | 2020<br>£ |
|--|-----------|-----------|
| Forum expenses                           | 17,217    | 44,730    |
| Management fees                          | 650       | 875       |
|  | 17,867    | 45,605    |
| Grant funding of activities (see note 7) | 1,050     | 6,000     |
| Share of support costs (see note 8)      | 27,932    | 26,677    |
| Share of governance costs (see note 8)   | 6,480     | 7,614     |
|  | 53,329    | 85,896    |
| <b>Analysis by fund</b>                  |           |           |
| Unrestricted funds - general             | 53,329    | 85,896    |

### 7 Grants payable

|                       | 2021<br>£ | 2020<br>£ |
|-----------------------|-----------|-----------|
| Grants to individuals | 1,050     | 6,000     |
|                       | 1,050     | 6,000     |



# UK MYELOMA FORUM

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

### FOR THE YEAR ENDED 31 MARCH 2021

#### 8 Support costs

|                       | Support costs | Governance costs | 2021          | Support costs | Governance costs | 2020          |
|-----------------------|---------------|------------------|---------------|---------------|------------------|---------------|
|                       | £             | £                | £             | £             | £                | £             |
| Staff costs           | 27,932        | -                | 27,932        | 26,677        | -                | 26,677        |
| Accountancy           | -             | 6,480            | 6,480         | -             | 7,614            | 7,614         |
|                       | <u>27,932</u> | <u>6,480</u>     | <u>34,412</u> | <u>26,677</u> | <u>7,614</u>     | <u>34,291</u> |
| Analysed between      |               |                  |               |               |                  |               |
| Charitable activities | <u>27,932</u> | <u>6,480</u>     | <u>34,412</u> | <u>26,677</u> | <u>7,614</u>     | <u>34,291</u> |

Governance costs includes payments to the independent examiner of £2,640 (2020: £2,520) for independent examination fees and £3,840 (2020: £5,094) for accountancy services.

#### 9 Trustees

None of the trustees (or any persons connected with them) received any remuneration or benefits from the charity during the year whereas 10 of the trustees were reimbursed £3,313 for travel expenses in 2020.

#### 10 Employees

##### Number of employees

The average monthly number employees during the year was.

|                         | 2021<br>Number | 2020<br>Number |
|-------------------------|----------------|----------------|
| Administration          | <u>1</u>       | <u>1</u>       |
| <b>Employment costs</b> | <b>2021</b>    | <b>2020</b>    |
|                         | <b>£</b>       | <b>£</b>       |
| Wages and salaries      | 27,312         | 26,068         |
| Other pension costs     | 620            | 609            |
|                         | <u>27,932</u>  | <u>26,677</u>  |

Key management personnel are the trustees and they received no remuneration during the current or prior year.

There were no employees whose annual remuneration was £60,000 or more in the current or prior year.

# UK MYELOMA FORUM

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

### FOR THE YEAR ENDED 31 MARCH 2021

#### 11 Net gains/(losses) on investments

|                                    | Unrestricted<br>funds<br>designated<br>2021<br>£ | Unrestricted<br>funds<br>designated<br>2020<br>£ |
|------------------------------------|--|--|
| Revaluation of investments         | 38,443   | (28,984)   |
| Gain/(loss) on sale of investments | 2,723  | 1,389  |
|                                    | <u>41,166</u>                                    | <u>(27,595)</u>                                  |

#### 12 Fixed asset investments

|                                | Listed<br>investments<br>£ | Cash in portfolio | Total<br>£     |
|--------------------------------|----------------------------|-------------------|----------------|
| <b>Cost or valuation</b>       |                            |                   |                |
| At 1 April 2020                | 161,955                    | 12,193            | 174,148        |
| Additions                      | 18,657                     | (18,657)          | -              |
| Valuation changes              | 38,443                     | -                 | 38,443         |
| Dividend and interest received | -                          | 4,334             | 4,334          |
| Management fee                 | -                          | (1,436)           | (1,436)        |
| Disposals                      | (17,193)                   | 19,916            | 2,723          |
|                                | <u>201,862</u>             | <u>16,350</u>     | <u>218,212</u> |
| At 31 March 2021               | 201,862                    | 16,350            | 218,212        |
|                                | <u>201,862</u>             | <u>16,350</u>     | <u>218,212</u> |
| <b>Carrying amount</b>         |                            |                   |                |
| At 31 March 2021               | 201,862                    | 16,350            | 218,212        |
|                                | <u>201,862</u>             | <u>16,350</u>     | <u>218,212</u> |
| At 31 March 2020               | 161,955                    | 12,193            | 174,148        |
|                                | <u>161,955</u>             | <u>12,193</u>     | <u>174,148</u> |

#### 13 Debtors

|   | 2021<br>£  | 2020<br>£    |
|---|------------|--------------|
| <b>Amounts falling due within one year:</b> |            |              |
| Other debtors                               | 283        | 1,430        |
|   | <u>283</u> | <u>1,430</u> |

#### 14 Creditors: amounts falling due within one year

|                                    | 2021<br>£    | 2020<br>£     |
|------------------------------------|--------------|---------------|
| Other taxation and social security | -            | 1,439         |
| Other creditors                    | 178          | -             |
| Accruals and deferred income       | 5,880        | 45,900        |
|                                    | <u>6,058</u> | <u>47,339</u> |

## UK MYELOMA FORUM

### NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

#### FOR THE YEAR ENDED 31 MARCH 2021

#### 15 Designated funds

The income funds of the charity include the following designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes:

|                                | Movement in funds          |                       |                       |                                   |                            | Movement in funds     |                       |                                   |                             |
|--------------------------------|----------------------------|-----------------------|-----------------------|-----------------------------------|----------------------------|-----------------------|-----------------------|-----------------------------------|-----------------------------|
|                                | Balance at<br>1 April 2019 | Incoming<br>resources | Resources<br>expended | Revaluations,<br>gains and losses | Balance at<br>1 April 2020 | Incoming<br>resources | Resources<br>expended | Revaluations,<br>gains and losses | Balance at<br>31 March 2021 |
|                                | £                          | £                     | £                     | £                                 | £                          | £                     | £                     | £                                 | £                           |
| Michael Morley Investment Fund | 256,988                    | 5,297                 | (1,542)               | (27,595)                          | 233,148                    | 4,334                 | (1,436)               | 41,166                            | 277,212                     |
|                                | <u>256,988</u>             | <u>5,297</u>          | <u>(1,542)</u>        | <u>(27,595)</u>                   | <u>233,148</u>             | <u>4,334</u>          | <u>(1,436)</u>        | <u>41,166</u>                     | <u>277,212</u>              |
|                                | <u><u>256,988</u></u>      | <u><u>5,297</u></u>   | <u><u>(1,542)</u></u> | <u><u>(27,595)</u></u>            | <u><u>233,148</u></u>      | <u><u>4,334</u></u>   | <u><u>(1,436)</u></u> | <u><u>41,166</u></u>              | <u><u>277,212</u></u>       |

The designated fund is used to hold the Charity's investments and generate income.

# UK MYELOMA FORUM

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

### FOR THE YEAR ENDED 31 MARCH 2021

#### 16 Analysis of net assets between funds

|  | Unrestricted   | Designated     | Total          | Unrestricted  | Designated     | Total          |
|--|----------------|----------------|----------------|---------------|----------------|----------------|
|  | 2021           | 2021           | 2021           | 2020          | 2020           | 2020           |
|  | £              | £              | £              | £             | £              | £              |
| Fund balances at 31 March 2021 are represented by: |                |                |                |               |                |                |
| Investments  | -              | 218,212        | 218,212        | -             | 174,148        | 174,148        |
| Current assets/(liabilities)                       | 137,617        | 59,000         | 196,617        | 57,357        | 59,000         | 116,357        |
|  | <u>137,617</u> | <u>277,212</u> | <u>414,829</u> | <u>57,357</u> | <u>233,148</u> | <u>290,505</u> |

#### 17 Analysis of changes in net funds

The charity had no debt during the year.

#### 18 Related party transactions

There were no disclosable related party transactions during the year (2020 - none).